Formycon and Bioeq Report the US FDA’s Acceptance of BLA for FYB201 (biosimilar, ranibizumab)

Shots:

• The US FDA has accepted the BLA for FYB201, a biosimilar referencing Lucentis for review and assigned a target action date for the application for Aug’2022
• Following the approval, Coherus will commercialize FYB201 in the US whereas Formycon will participate economically in US sales through its interest in royalties paid by Coherus to Bioeq
• Lucentis is used in the treatment of neovascular (wet) macular degeneration and acts by inhibiting VEGF, which is responsible for the excessive formation of blood vessels in the retina

Click here to­ read full press release/ article | Ref: Formycon | Image: Formycon